How I use the latest technology to investigate and treat a person with Type 1 Diabetes. Dr Pratik Choudhary

Similar documents
Managing Problematic Hypoglycaemia Pratik Choudary

PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)

The artificial pancreas: the next step in connectivity and digital treatment of type 1 diabetes

Insulin Pumps and Glucose Sensors in Diabetes Management

What is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming

Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM

Diabetes Management: Current High Tech Innovations

1. Continuous Glucose Monitoring

UNCOVERING THE BENEFITS OF THE ACCU- CHEK BOLUS ADVISOR MICHAEL PORTER CDE

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION

What is the role of insulin pumps in the modern day care of patients with Type 1 diabetes?

Presented by Dr. Bruce Perkins, MD MPH Dr. Michael Riddell, PhD

Using the Bolus Wizard Calculator

When Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida

1. What s the point of a network the case for research? 2. How to use CSII effectively

Pump and Sensor Data Interpretation. Irl B. Hirsch, MD University of Washington School of Medicine

Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim

Applications of Technologies to Your Patient. Irl B. Hirsch, MD Professor of Medicine University of Washington School of Medicine Seattle, Washington

Pumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University

Exercise Prescription in Type 1 Diabetes

The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections

Insulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)

Counting the Carbs, Fat and Protein in Type 1 Diabetes Translating the Research into Clinical Practice

Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections. Aaron Michels MD

The Realities of Technology in Type 1 Diabetes

NEWS BRIEFING Advances in Technology. moderated by: Irl Hirsch, MD University of Washington Medical Center

Emerging Automated Insulin Delivery Systems

The next five years in diabetes technology: closed-loop systems

Pump Failure Guidelines

National Best Practice Guides: Inpatients on Continuous Subcutaneous Insulin Infusion (CSII)

Interpretation and management of fasting hyperglycaemia in adults with Type 1 diabetes using MDI insulin regimen

Case Study: Competitive exercise

7/18/2017. Everything discussed in this presentation is off-label. (And that s ok.) Dana Lewis Founder, #OpenAPS WARNING: Disclosure to Participants

Update on Continuous Glucose Monitoring (CGM) Technology in Diabetes. Elena Toschi, MD November 12, 2016

Advances in Diabetes Care Technologies

Advances in Diabetes Care Technologies

More Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center

hypoglycaemia unawareness keystone 18 July 2014

Update on Diabetes Technology

Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?

CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION

Making the Most of Continuous Glucose Monitoring

Diabetes Technology in Irl B. Hirsch, MD University of Washington School of Medicine Seattle, WA

Using and Interpreting Diabetes Data. Irl B. Hirsch, MD University of Washington

EAST OF ENGLAND CHILDREN AND YOUNG PEOPLE S DIABETES NETWORK. Optimising Glycaemic Control for Children and Young People with Diabetes

Glucometers Gastrostomy Tubes Nasogastric Tubes Insulin pumps Continuous Glucose monitoring system Closed Loop Smart phones/tablets

BASICS OF INSULIN PUMPS. Jennifer Okemah MS RD BCADM CDE CSSD

Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??

Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES

Diabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE

15 th Annual DAFNE collaborative meeting Tuesday 28 th June 2016

Faculty Disclosure. No, nothing to disclose Yes, please specify: Novo-Nordisk. Roche. Abbott. Funded Research. Ownership/ Equity Position

Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico

Automated insulin delivery in response to CGM data (looping)

Real-Time Continuous Glucose Monitoring: From Application to Evaluation

Technology in Diabetes Management Irl B. Hirsch, MD University of Washington

CGM and Closing The Loop

Report Reference Guide

WOULD YOU LIKE MORE CONFIDENCE IN YOUR HYPOGLYCAEMIC CONTROL? SMARTGUARD. PROVIDES PREDICTIVE PROTECTION

These comments are an attempt to summarise the discussions at the manuscript meeting. They are not an exact transcript.

15 th Annual DAFNE collaborative meeting Tuesday 28 th June 2016

PROTOCOL FOR HYBRID CLOSED LOOP TECHNOLOGY

Pregnancy workshop. 25 th April 2014 Caroline Byrne

Flash Glucose Monitoring & Implantable Sensors

Diabetes Technology for the Endocrinologist, Irl B. Hirsch, MD University of Washington

CareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes

Guide to Flexible Insulin Therapy for Families

Optimizing Therapy and Clinical Outcomes Using Real-Time Continuous Glucose Monitoring (AADE PRODUCT THEATRE) August 7, 2014 Orlando, FL

WHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES?

Making Sense of Glucose Monitoring. My Journey with Glucose Monitoring Over the Last 37 Years 8/7/2017

THE SHEFFIELD AREA PRESCRIBING GROUP. Position Statement for Prescribing of Freestyle Libre In Type 1 Diabetes. Date: March 2018.

Maternal and Fetal Complications in Diabetes Pregnancy

7/18/2017. An Educator s Use of Outpatient Insulin Dosing Decision Support Software. Disclosure to Participants. Bruce Bode MD.

Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)

The In-Clinic Close Loop Experience in the US

MINIMED 640G WITH SMARTGUARD GIVES YOU CONFIDENCE TO TAKE CONTROL OF YOUR DIABETES

Evidence and Guidelines TECHNOLOGY 2016 Tina Kader, MD

Clinical News and Innovation in Type 1 Diabetes and Technology. Parth Narendran University Hospitals Birmingham

Report Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1

DIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson

TYPE 1 DIABETES AND EXERCISE. Mark W Savage

Today s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures

Diabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018

Objectives. Glucose Monitoring Today. Tracking Glucose ISO Standards. Continuous Glucose Monitoring & Diabetes Management 3/7/2015

CARELINK PERSONAL ACTIONABLE INSIGHTS FOR BETTER DIABETES MANAGEMENT CARELINK REPORTS GUIDE

ATTD Session: Needs and solutions in Type 1 diabetes from youth to seniors: towards software prescriptions

Why (and how) I built an artificial

Advances in Diabetes Care Technologies

Hybrid Closed Loop Status & Practical Challenges in Implementation

Insulin Initiation and Intensification. Disclosure. Objectives

Updates in Diabetes Technology

Insulin pump therapy. Healthy Living with Diabetes

Using Insulin in the Primary Care Setting: Interactive Cases

Do fat and protein affect post prandial glycemia in the outpatient real world setting? Neha Verma, MD Robert Melfi, MD

THERAPY MANAGEMENT SOFTWARE FOR DIABETES

Do women have to come off DAFNE when pregnant?

Understanding the CareLink TM Therapy Management Dashboard Report

Technology in Diabetes Care: Emerging Level

Lessons From The Type 1 Diabetes Exchange

CGM: Continuous Glucose Monitoring Making Sense of It All AW: ANCO/GEND/1016/0117

Transcription:

How I use the latest technology to investigate and treat a person with Type 1 Diabetes Dr Pratik Choudhary

Disclosures Advisory board and speaker fees from Medtronic, Roche, Abbott and Johnson and Johnson, Sanofi, Lilly, Novo Nordisk, MSD, BI Research support - Medtronic, Beta O2, Diabetes UK, JDRF, Keen to try any new technology Dr Pratik Choudhary

Control Hypoglycaemia

Case vignette Sarah aged 43yrs, T1D 24 years HbA1c 8.8% Rapid insulin 10 10 12 Background 18 Measures BG 2 3 / day From memory BG 5-15 variable Hypo 2-3 / week Guestimates doses.

Levels of Care Fixed Doses OD Basal CHO Counting BD Basal CHO Counting BD Basal OR CSII 6 + 6 + 6 20 2-3 tests/day Visual estimation Guessed corrections 1:1 + 1:1+ 1:1 12 12 ISQ = 3 4 tests/day Pre-meal boluses 1:1 + 1:1+ 1:1 12 12 ISQ = 3 6-8 tests/day OR CGM Adjustments for ex Adjust for Fat/prot Pattern recognition P Choudhary.

Why do you think she is not at target? Education Skills Tools Support Confidence Motivation Presentation title 6

The Building Blocks Structural Behavioural Basal Day / Night Carb Counting N of BG / day Bolus Insulin: Carb Ratios Correction Ratios Adjusting basal for exercise / illness Over-correcting highs and lows Presentation title 7

Mimicking physiology Basal Basal secretion represented 50.1±3.1% of the total 24-h insulin secretion in normal subjects and 45.2±2.2% in obese patients (P < 0.2). polonsky et al, JCI, 1998 8

Mean HbA 1c 11.0 % 10.5 % 10.0 % 9.5% 9.0% 8.5% 8.0% 7.5% 7.0% Relationship between CBG frequency and HbA 1c SMBG per day 1 HbA 1c (%) 11 10 9 8 7 Frequency of daily SMBG 2 6.5% 0-2 3-4 5-6 7-8 9-10 11-12 13 0 0 1 2 3 4 5 6 7 8 9 10 SMPG per day 1. Miller KM et al., Diabetes Care 2013; 36:2009-14 2. Ziegler R et al. Ped Diabetes 2011; 12: 11-17. Frequency of daily SMPG MDI CSII

Dose adjustment Carb Food content insulin Insulin: Carb BG Correction - target glucose insulin Insulin sensitivity factor Insulin on board 65 [ 6.5] 10 12-6 3 [ 2 ] Insulin : Carb ratio 1 : 10 gms Correction factor = 3 Current glucose = 12 mmol/l Insulin on board Rules ICR = 350 / TDD ISF = 120 / TDD Pratik Choudhary

SMART METERS Bolus calculators average glucose [ HbA1c] Data analysis - real time Real time data upload

Timing is everything Bolus 20 minutes before meals Blood glucose (mmol/l) 13.9 12.5 11.1 9. 7 8. 3 Bolus 20 min after meal Bolus 20 min before Bolus at meal start Pre (-20) Start (0) Post (+20) 6. 9 5. 6 0 30 60 90 12 0 15 0 18 0 21 0 24 0 Time post meal (min) Cobry et al Diabetes Technol Ther 2010; 12: 173-177

What education can deliver 20-50% achieve A1c < 7.5% depending on centre For the majority, not enough to achieve < 7.0%

Proportion in range 100 80 60 28.9% 40.6% 55.6% % Above Target % In Target % Below Target 40 20 57.3% 50.6% 39.9% Figure 1: Proportion of daily CBG results above, below and within the target range amongst the varying HbA1c groups. 0 HbA1c <7.5 HbA1c 7.5 8.9 HbA1c 9 Sivasubramaniyam S et al., Diabet Med 2017; 34 (10): 1456-1460. Dr Pratik Choudhary

6 months later Done DAFNE HBA1c dropped to 8% BUT Had a few night time hypos So Overnight insulin reduced But HBA1c is now 8.4%

P Choudhary Using blinded Continuous glucose monitoring

Overnight and fasting glucose High x 2 nights OK x 2 nights Low x 3 nights A typical week in the life of T1D How do you adjust overnight basal?

Variability in overnight insulin requirements Ruan et al., Diabetes Care 2016; 39(5): 830-832.

Continuous glucose monitoring 10% IN CONTROL 9% JDRF(age 8-24) HbA1C 8% RealTrend JDRF<7 IMPACT Danne et al Ly et al. 7% ASPIRE IN HOME Choudhary et al. 6% Low Hypoglycaemia High Dr Pratik Choudhary Slattery et al, Diabetes Tech Ther; 2017 19

CGM can help reduce HbA1c Lind M, et al JAMA. 2017;317(4):363-364.

Alarms are not enough Patients sleep through up to 71% of nocturnal alarms Buckingham et al Diabetes Technol Ther. 2005 Dr Pratik Choudhary 21

Case study for CGM Life changing Able to travel independently Husband able to leave her alone with her children NO further severe hypos Able to get driving license back

Other technology to support people with type 1 diabetes 23

T1 resources.uk

Virtual clinics HCP: HCP PWD: HCP

Dr Pratik Choudhary, KCL

Basic principles Delay in glucose sensing Algorithmic delays Delay in insulin action

Patients pushing the boundries #wearenotwaiting #OpenAPS #nightscout Page 28

Cellular therapies Recurrent severe hypoglycemia despite optimised medical therapy 70% graft survival at 5 years 30% insulin independence

Summary Get the data Teach the patient how to use the data Think of the split between background and rapid acting insulin Timing of the rapid acting is key Better monitoring and better delivery can help Frequent virtual contact helps Presentation title 30